Abstract
Halogenated anesthetic agents (desflurane, isoflurane and sevoflurane) may have cardioprotective properties at therapeutic doses against myocardial intraoperative ischemia-reperfusion injury. Cardioprotection mechanisms are related to mitochondrial and anti-apoptotic signaling pathways. Experimentals and human studies have proven that their use may reduce morbidity and mortality in the setting of cardiac surgery, including a reduction in myocardial infarct size and mechanical ventilation needs. In contrast, total intra-venous propofol based anesthesia may be detrimental. In the present review, we show the rationale for the perioperative use of halogenated anesthetics based on mechanisms of action, experimental research and human studies. Considerations and major concerns regarding their use, the present evidence for their use in other areas, such as major non-cardiac surgery and intensive care unit patients, and future perspectives are also discussed.
Keywords: Halogenated agents, total intra-venous anesthesia, cardiac surgery, outcomes, intensive care unit, anesthesia, intensive care.
Graphical Abstract
Current Vascular Pharmacology
Title:Halogenated Agents and Cardiovascular Surgery: Has Mortality Really Decreased?
Volume: 16 Issue: 4
Author(s): Giovanni Landoni*, Juan Carlos Lopez-Delgado, Chiara Sartini, Simona Tamà and Alberto Zangrillo
Affiliation:
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan,Italy
Keywords: Halogenated agents, total intra-venous anesthesia, cardiac surgery, outcomes, intensive care unit, anesthesia, intensive care.
Abstract: Halogenated anesthetic agents (desflurane, isoflurane and sevoflurane) may have cardioprotective properties at therapeutic doses against myocardial intraoperative ischemia-reperfusion injury. Cardioprotection mechanisms are related to mitochondrial and anti-apoptotic signaling pathways. Experimentals and human studies have proven that their use may reduce morbidity and mortality in the setting of cardiac surgery, including a reduction in myocardial infarct size and mechanical ventilation needs. In contrast, total intra-venous propofol based anesthesia may be detrimental. In the present review, we show the rationale for the perioperative use of halogenated anesthetics based on mechanisms of action, experimental research and human studies. Considerations and major concerns regarding their use, the present evidence for their use in other areas, such as major non-cardiac surgery and intensive care unit patients, and future perspectives are also discussed.
Export Options
About this article
Cite this article as:
Landoni Giovanni *, Lopez-Delgado Carlos Juan , Sartini Chiara , Tamà Simona and Zangrillo Alberto , Halogenated Agents and Cardiovascular Surgery: Has Mortality Really Decreased?, Current Vascular Pharmacology 2018; 16 (4) . https://dx.doi.org/10.2174/1570161115666171010121549
DOI https://dx.doi.org/10.2174/1570161115666171010121549 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Subretinal Transplantation of Rat MSCs and Erythropoietin Gene Modified Rat MSCs for Protecting and Rescuing Degenerative Retina in Rats
Current Molecular Medicine Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Potential Applications of Hydrogen Sulfide-Induced Suspended Animation
Current Medicinal Chemistry Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Current Drug Targets Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Neuroprotective and Preventative Effects of Molecular Hydrogen
Current Pharmaceutical Design Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology